Table 3. Summary of effect sizes (weighted mean difference) for secondary outcomes.
Variables | No. of comparison | Sample size | Net change(95%CI) | P | Test for heterogenenity | ||
T | C | I2(%) | P | ||||
HOMA index | 3 | 70 | 71 | −0.32(−0.65,0.01) | 0.06 | 89 | 0.0001 |
Postprandial glucose | 3 | 69 | 69 | −0.20(−1.07,0.67) | 0.65 | 0 | 0.77 |
Triglyceride(mmol/l) | 8 | 201 | 212 | −0.02(−0.29,0.25) | 0.90 | 96 | <0.0001 |
Total-C(mmol/l) | 9 | 254 | 252 | −0.29(−0.85,0.27) | 0.31 | 99 | <0.0001 |
HDL-c(mmol/l) | 9 | 217 | 223 | −0.00(−0.03,0.02) | 0.70 | 20 | 0.27 |
LDL-c(mmol/l) | 8 | 192 | 203 | −0.24(−0.78,0.29) | 0.37 | 98 | <0.0001 |
HOMA, homeostasis model assessment; Total-C, total cholesterol; HDL-C, high-density lipoprotein-cholesterol;LDL-C, low-density lipoprotein-cholesterol; CI, confidence interval. T: treatment group; C: control group.